Objectives: The optimal duration of antibiotic treatment in patients with bloodstream infections remains contentious, with concerns regarding both undertreatment and the encouragement of antibiotic resistance. In our ICU we traditionally use short-course antibiotic monotherapy as the mainstay of treatment. We sought to document the impact of this strategy on pathogen type, resistance patterns and patient outcomes. A comparison was made against data collected during a similar exercise in 2000.
Introduction
The Extended Study on Prevalence of Infection in Intensive Care (EPIC) II point prevalence study of 1265 ICUs reported that 7087 (51.4%) of 13 796 patients were infected on the day of survey, with bloodstream infection documented in 1071 (15.1%). 1 Notably, 71% of the entire cohort was receiving antibiotics for either treatment or prophylaxis, and 16% were receiving antifungal agents. While infection is a major contributor to patient mortality and morbidity, 1 -6 the overuse of antibiotics, in particular an extended duration of therapy, 7 -9 continues to drive increasing antibiotic resistance. This in turn is associated with worse outcomes. 10 However, minimal evidence exists to guide the optimal treatment duration for bacteraemic patients. 11 In our general medical-surgical ICU, short-duration antibiotic therapy lasting 5 days, predominantly involving only monotherapy, has been the standard of care unless a specific infection, e.g. endocarditis, tuberculosis or osteomyelitis, mandates a longer course of treatment. We previously reported on treatment duration, resistance patterns and outcomes in 84 consecutive ICU patients with positive blood cultures due to infection acquired in the community, ward and/or ICU over a 6 month period from 1 February to 31 July 2000. 12 There was a low incidence of antimicrobial resistance, and a satisfactory clinical response with 13 we repeated this observational study in bacteraemic patients admitted to the same ICU between December 2012 and May 2013. We sought to determine whether changes had occurred in the incidence of bacteraemia, microbiological spectrum and resistance patterns, antibiotic strategy (including duration) and patient outcomes.
Patients and methods
The University College London Hospitals ICU is a 35 bed general medicalsurgical unit now admitting .2500 adult elective surgical and emergency patients per year. Cardiac surgical, neurosurgical and paediatric patients are admitted to sister ICUs. Trauma patients are mainly admitted to local hospitals with trauma centres. The unit receives daily visits from a consultant microbiologist except on Sundays.
The source population consisted of all patients admitted to the ICU from 1 December 2012 to 31 May 2013 who either had community-or hospital-acquired bacteraemia, or who subsequently developed bacteraemia while in ICU. A comparison was made against data collected over a 6 month period from 1 February to 31 July 2000 when the ICU had 22 beds 12 and was located in an older building. The patient population was broadly similar, and included immunosuppressed patients with haematological and other malignancies.
In the first study period, blood cultures were often collected from vascular catheters already in situ, whereas following a change in unit policy, blood cultures were only collected using a fresh stab over the second study period. In both periods blood cultures were only taken for a clinical indication rather than for any routine background surveillance or screening.
Clinical, microbiological and outcome data were obtained from the ICU, microbiology and hospital databases. Patients were included if they had microbiologically confirmed bacteraemia or fungaemia and fulfilled the diagnosis of bloodstream infection according to predefined criteria. The same definitions were used as for the 2000 study, as shown in the Supplementary data (available at JAC Online). Being a retrospective database audit, Ethics Committee permission was not sought.
Patient characteristics and findings for both the frequency and sites of bloodstream infections were compared for the two study periods. Data were also collected on resistance patterns, antibiotic type and duration, and patient outcomes. We have not reported data on the types of antibiotic used but these are broadly identical across the two periods. Cephalosporins are generally used as first-line agents for community-acquired infections, and piperacillin/tazobactam as first-line therapy for hospital-or ICU-acquired presumed Gram-negative infection, with meropenem reserved for subsequent infections, and an occasional use of gentamicin for complicated Gram-negative infections. Where staphylococcal infection is suspected, flucloxacillin is used as a first-line therapy where methicillin resistance is unlikely (e.g. community acquired and not recently hospitalized); otherwise teicoplanin is used.
We considered statistical comparisons to be inappropriate as this is a purely descriptive comparison of practices, outcomes and resistance patterns 13 years apart, with some alterations in denominator values, in particular patient numbers and altered blood sampling techniques.
Results
The total number of ICU admissions increased from 713 patients in the 6 month study period in 2000, to 1318 patients in 2013. Table 1 summarizes the characteristics of patients in whom bacteraemia or fungaemia was found during these study periods. In 2000, 102 episodes of bacteraemia or fungaemia occurred in 84 of the 713 patients (11.8%). By comparison, there were 113 episodes among 87 admissions (6.6%) in 2013, of which 14 episodes occurred in just two patients with complicated intra-abdominal sepsis. In the 2013 cohort more patients were admitted with community-acquired bacteraemia but fewer suffered ICU-acquired bacteraemia. (Table 1) . Specifically, there were no subsequent episodes of either endocarditis or osteomyelitis.
The sites of infection are shown in Figure 2 . More patients with primary or respiratory tract-related bacteraemia were admitted in 2013, but there were fewer cases of ICU-acquired catheterrelated bacteraemia.
Short-course monotherapy was used in the majority of patients both in 2000 and in 2013 (73.5% in 2000, 65.7% in 2013) ( Table 2) . While proportionally more patients received combination therapy for ICU-acquired bacteraemia, this was due in part to the declining number of cases of line-related bacteraemia (which is generally treated with monotherapy), and the increasing number of patients with haematological malignancy (18 versus 11) . Of these 18, 12 received combination antibiotic therapy.
The median duration of antibiotic treatment did not change over time. The hospital mortality of bacteraemic patients was 45% in the 2000 cohort, and 32% in the 2013 cohort. De Santis et al.
Discussion
Our long-standing strategy of a predominant use of short-course (5 day) antibiotic monotherapy given to ICU patients for community-, hospital-and ICU-acquired bacteraemia remains associated with a continued low level of antibiotic resistance and fungaemia, and low rates of breakthrough and relapse bacteraemia. Hospital mortality in the bacteraemic/fungaemic patients improved from 45% in 2000 to 32% in 2013. In conjunction with national data, 14 the rate of MRSA infection has dropped markedly in recent years and no ICU-acquired MRSA bacteraemia was reported in the 2013 period.
The number of catheter-related ICU-acquired bacteraemias also fell from 27 in the 2000 cohort to 8 in the 2013 cohort. While this is related in part to the introduction of a care bundle for the prevention of intravascular catheter infection and to the earlier removal of catheters, the change in ICU policy to taking blood cultures only from fresh sites (venous or arterial) may be contributory.
A recent systematic review and meta-analysis by Havey et al.
15
was able to find 24 trials totalling 227 patients who were allocated to 'shorter' (5 -7 days) versus 'longer' (7 -21 days) durations of treatment, with outcome data available for only 155 patients. No significant differences were noted in clinical or microbiological cure rates or patient survival, although the small sample sizes were acknowledged. The same group performed a national practice survey among Canadian infectious disease and critical care specialists who recommended treatment durations of 7-14 days for bacteraemia related to central venous catheters, pneumonia and urinary tract, skin and soft tissue or intra-abdominal infection. 16 Longer durations (mean 13.5+4.8 days) were recommended for Staphylococcus aureus infections and shorter periods (5.7+4 days) for CoNS. Bacteraemia trends in a single ICU 275 JAC Notably, the use of multiple and/or prolonged duration antibiotics has been associated with worse outcomes in several recent observational studies. In a multicentre observational study, Kett et al. 17 found a significantly higher survival rate (79% versus 65%) in patients with suspected MDR pneumonia who received therapy not compliant with national guidelines recommending at least two antibiotics active against Gram-negative organisms plus one antibiotic against MRSA. In a single-centre before-after study, Hranjec et al. 18 reported a significantly increased 2.5-fold increased mortality risk when adopting an aggressive antibiotic approach to treating infection on their surgical ICU; 20% of patients had bacteraemia. Of note, the duration of antibiotic therapy was significantly lower in the conservative (delayedtreatment) group. In a multicentre study Jensen et al. 19 reported that procalcitonin-guided antimicrobial escalation increased the duration of antibiotics from a median of 4 days (IQR 3 -10) to 6 days (IQR 3 -11) and that this was associated with organrelated harm and a longer ICU stay. In a multicentre prospective observational study conducted in 2010, we were not able to show an impact of antibiotics on mortality in treating bacteraemia in critically ill patients. 20 A wide variability in antibiotic usage may be responsible, 21 especially as a recent study of 628 patients with severe sepsis and septic shock, of whom 241 patients (38.4%) had bacteraemia, demonstrated lower mortality rates in those in whom antibiotic therapy was de-escalated. 22 In addition to direct patient outcomes, the importance of shorter antibiotic courses to reduce the selective pressure on bacterial flora and the prevent emergence of resistance has been emphasized. 7 -9 This is particularly pertinent as mortality rates are higher in critically ill patients with MDR organisms 10, 23 while antimicrobial resistance is on the rise worldwide, particularly with Gram-negative organisms. 24 -26 Likewise, nosocomial candidaemia is associated with high levels of both crude and attributable mortality. 27 A prospective surveillance study revealed that infection with a fluconazoleresistant Candida species was associated with prior exposure to carbapenems, trimethoprim/sulfamethoxazole, clindamycin and colistin. 28 The lack of any fluconazole-resistant Candida species in our 2013 cohort may thus be linked to the short-course antibiotic strategy in use.
The limitations of our study include the use of only singlecentre data that were collected retrospectively, with the establishment of the diagnosis and source of the infection depending on the quality of documentation. Thus, case ascertainment may De Santis et al.
have been incorrect in some instances. The number of cases of ICU-acquired bacteraemia fell in 2013, with a particular reduction noted in Enterococcus, Klebsiella and S. aureus, yet resistance patterns in the remaining cases did not alter. On the other hand, the number of community-and hospital-acquired cases increased, although resistance patterns also remained unchanged with the exception of hospital-acquired candidaemia, for which no fluconazole resistance was noted in 2013. In line with the UK in general, we have also seen an expansion in the number of critical care beds in the intervening 13 years. There have also been some changes in the subspecialty surgery performed at the hospital related to reorganizations within the London area, but the patient mix remains broadly similar in terms of the percentages of medical, surgical, oncological and immunosuppressed populations. The particular demographic mix of our ICU patient population, including a large number of immunosuppressed patients with, for example, haematological malignancy, alcoholic liver disease and/or HIV, and patients with complex abdominal failure, makes it difficult to draw a direct comparison against outcomes in other ICUs. Even in our high-risk population, our antibiotic strategy appears to be successful in terms of good patient outcomes and the maintenance of low resistance rates, especially when compared with the rising incidence of resistance reported in many countries including the USA and Europe.
In conclusion, the apparent success of our strategy over many years, with continued low levels of antimicrobial resistance and breakthrough or relapse bacteraemia with the same organism, does suggest the efficacy and safety of this short-course antibiotic approach. Ideally, prospective controlled studies should be performed in other ICUs to confirm these findings, with extension over several years to monitor antibiotic resistance patterns. Whether this restricted antibiotic strategy can also impact positively upon units with an established problem with antibiotic resistance merits separate investigation.
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